Novo Integrated Sciences Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 2/6

Novo Integrated Sciences şirketinin toplam hissedar öz sermayesi $9.7M ve toplam borcu $2.6M olup, bu da borç-öz sermaye oranını 26.4% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $35.3M ve $25.7M dir.

Anahtar bilgiler

26.4%

Borç/özkaynak oranı

US$2.55m

Borç

Faiz karşılama oranı	n/a
Nakit	US$1.54m
Eşitlik	US$9.66m
Toplam yükümlülükler	US$25.66m
Toplam varlıklar	US$35.33m

Son finansal sağlık güncellemeleri

Recent updates

Slammed 49% Novo Integrated Sciences, Inc. (NASDAQ:NVOS) Screens Well Here But There Might Be A Catch

Jul 11

Novo Integrated Sciences, Inc. (NASDAQ:NVOS) Looks Just Right With A 26% Price Jump

Apr 18

Novo Integrated Sciences prices 4M unit public offering at $.50/unit

Oct 14

Novo Integrated Sciences expects to report over fivefold increase in Q3 revenue

Jul 11

Health Check: How Prudently Does Novo Integrated Sciences (NASDAQ:NVOS) Use Debt?

Nov 23

Does Novo Integrated Sciences (NASDAQ:NVOS) Have A Healthy Balance Sheet?

Aug 07

Does Novo Integrated Sciences (NASDAQ:NVOS) Have A Healthy Balance Sheet?

Mar 02

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: NVOS 'nin kısa vadeli varlıkları ( $6.2M ) kısa vadeli yükümlülüklerini ( $22.7M ) kapsamıyor.

Uzun Vadeli Yükümlülükler: NVOS şirketinin kısa vadeli varlıkları ( $6.2M ) uzun vadeli yükümlülüklerini ( $3.0M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: NVOS 'nin net borç/öz sermaye oranı ( 10.5% ) tatmin edici olarak değerlendirilmektedir.

Borcun Azaltılması: NVOS şirketinin borç/öz sermaye oranı son 5 yılda 9.8% seviyesinden 26.4% seviyesine yükseldi.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: NVOS şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: NVOS un, serbest nakit akışı her yıl % 31.7 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

Novo Integrated Sciences Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 2/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Novo Integrated Sciences Intends to Request Hearing Before Nasdaq Hearing Panel

Novo Integrated Sciences, Inc. announced delayed 10-Q filing

Novo Integrated Sciences, Inc. Receives A Notification Letter from the Nasdaq Stock Market, LLC

Novo Integrated Sciences, Inc. announced delayed 10-Q filing

Novo Integrated Sciences, Inc. announced delayed annual 10-K filing

Novo Integrated Sciences Announces 1-for-10 Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Price Requirement

Recent updates

Novo Integrated Sciences, Inc.(OTCPK:NVOS) dropped from S&P TMI Index

Novo Integrated Sciences, Inc.(OTCPK:NVOS) dropped from NASDAQ Composite Index

Novo Integrated Sciences, Inc., Annual General Meeting, Nov 22, 2024

Novo Integrated Sciences Intends to Request Hearing Before Nasdaq Hearing Panel

Novo Integrated Sciences, Inc. announced delayed 10-Q filing

Slammed 49% Novo Integrated Sciences, Inc. (NASDAQ:NVOS) Screens Well Here But There Might Be A Catch

Novo Integrated Sciences, Inc. (NasdaqCM:NVOS) acquired Ophir Collection, Llc.

Second quarter 2024 earnings released: US$0.16 loss per share (vs US$0.58 loss in 2Q 2023)

Novo Integrated Sciences, Inc. Announces Executive Changes

Novo Integrated Sciences, Inc. Receives A Notification Letter from the Nasdaq Stock Market, LLC

Novo Integrated Sciences, Inc. announced delayed 10-Q filing

Novo Integrated Sciences, Inc. announced delayed annual 10-K filing

Novo Integrated Sciences Announces 1-for-10 Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Price Requirement

Novo Integrated Sciences, Inc. (NasdaqCM:NVOS) announces an Equity Buyback for $5 million worth of its shares.

Novo Integrated Sciences, Inc.'s IoNovo for Kids receives Registration Number and Regulatory Approval by Turkey’s Ministry of Health

Novo Integrated Sciences, Inc.’ IoNovo Iodine Granted Registration Number and Regulatory Approval by Turkey’s Ministry of Health

Novo Integrated Sciences, Inc., Annual General Meeting, Sep 29, 2023

New minor risk - Revenue size

Third quarter 2023 earnings released: US$0.01 loss per share (vs US$0.13 loss in 3Q 2022)

Novo Integrated Sciences, Inc. Appoints Vivek Sethi as Principal Financial Officer

First quarter 2023 earnings released: US$0.12 loss per share (vs US$0.067 loss in 1Q 2022)

Novo Integrated Sciences, Inc. (NASDAQ:NVOS) Looks Just Right With A 26% Price Jump

High number of new and inexperienced directors

Novo Integrated Sciences Announces Receipt of Notice from Nasdaq

Novo Integrated Sciences, Inc. announced delayed 10-Q filing

Novo Integrated Sciences Announces Receipt of Notice from Nasdaq

Novo Integrated Sciences, Inc. announced delayed annual 10-K filing

Novo Integrated Sciences Receives A Notification Letter from Nasdaq Regarding Minimum Bid Price Requirements

High number of new and inexperienced directors

Novo Integrated Sciences, Inc. has completed a Composite Units Offering in the amount of $2 million.

Novo Integrated Sciences, Inc. has completed a Composite Units Offering in the amount of $2 million.

Novo Integrated Sciences prices 4M unit public offering at $.50/unit

Third quarter 2022 earnings released: US$0.13 loss per share (vs US$0.016 loss in 3Q 2021)

Novo Integrated Sciences, Inc. Provides Revenue Guidance for the Third Quarter of Fiscal Year 2022

Novo Integrated Sciences expects to report over fivefold increase in Q3 revenue

Novo Integrated Sciences, Inc., Annual General Meeting, Aug 19, 2022

Less than half of directors are independent

Second quarter 2022 earnings released: US$0.17 loss per share (vs US$0.056 loss in 2Q 2021)

Less than half of directors are independent

Novo Integrated Sciences, Inc. announced delayed 10-Q filing

Novo Integrated Sciences, Inc. announced delayed annual 10-K filing

Health Check: How Prudently Does Novo Integrated Sciences (NASDAQ:NVOS) Use Debt?

Novo Integrated Sciences, Inc. (NasdaqCM:NVOS) agreed to acquire Seven Pharmacies in the United States.

Does Novo Integrated Sciences (NASDAQ:NVOS) Have A Healthy Balance Sheet?

Third quarter 2021 earnings released: US$0.016 loss per share (vs US$0.004 loss in 3Q 2020)

Principal Financial Officer & Principal Accounting Officer Sterling Jimenez has left the company

Principal Financial Officer & Principal Accounting Officer has left the company

Second quarter 2021 earnings released: US$0.056 loss per share (vs US$0.022 loss in 2Q 2020)

Does Novo Integrated Sciences (NASDAQ:NVOS) Have A Healthy Balance Sheet?

Novo Integrated Sciences Announces Three New Independent Directors Appointments to Its Board of Directors and Formation of an Audit Committee

Novo Integrated Sciences, Inc. Announces Executive Changes

Novo Integrated Sciences, Inc. announced delayed annual 10-K filing

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin